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A B S T R A C T   
Introduction: We investigated the efficacy and acceptability of pharmacotherapy for dementia with Lewy bodies 
(DLB) while simultaneously considering the neuropsychiatric symptoms (NPS), cognitive function, motor 
symptoms, and acceptability. 
Methods: Electronic databases were searched from inception through June 5, 2019, for randomized controlled 
trials (RCTs) and open-label trials (OLTs) in patients with DLB. We performed a pairwise conventional meta- 
analysis (PWMA) and network meta-analysis (NMA) within a frequentist framework. The main outcomes were 
mean change scores in NPS, general cognition, motor symptoms and acceptability. The effect sizes and odds 
ratios with 95% confidence intervals (CIs) were calculated. This study was registered with PROSPERO 
(CRD42018096996). 
Results: In total, we included 29 studies (9 RCTs and 20 OLTs). In the NMA with 9 RCTs, both high- (mean 
difference [MD] 2.00, 95% CIs, 0.69 to 3.31) and low-dose (1.86, 0.58 to 3.15) donepezil were associated with a 
greater cognitive improvement than placebo. High-dose zonisamide was associated with greater motor symptom 
improvement ( -4.10, -7.03 to -1.17]). No medications reached statistical significance regarding improving 
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neuropsychiatric symptoms or developing intolerable adverse effects as compared to placebo. In the second 
NMA, with 29 studies as an exploratory analysis, aripiprazole and yokukansan may be effective for neuropsy-
chiatric symptoms, while levodopa may be associated with cognitive impairment. 
Conclusions: We report the most comprehensive evidence for the selection of pharmacotherapy for treating 
different clusters of DLB-related symptoms. Due to the limited availability of RCTs on DLB, more well-conducted 
RCTs are needed for MMA to warrant clinical efficacy in the future.   
Introduction 
The management of Dementia with Lewy bodies (DLB) is challenging 
and complex. Patient-centered intervention is often needed given the 
disease heterogeneity.1 To date, there is no effective therapy to cure DLB 
and symptomatic treatments show only a temporary and modest clinical 
effect.2 In addition, treatment for one of the core features of DLB may 
worsen another symptom. For example, the use of antipsychotic agents 
in patients with DLB with psychotic symptoms could not only cause 
irreversible parkinsonism but also cognitive impairment to some degree. 
1,3 Therefore, it is challenging for clinicians to choose appropriate 
strategies to treat patients with DLB. 
Lewy body disorders (LBD), which consist of Parkinson’s disease 
dementia (PDD) and DLB, are neurodegenerative diseases characterized 
by the accumulation of Lewy bodies in brain cells.4 Previous 
meta-analyses of DLB pharmacotherapy focused mainly on the whole 
group of LBD and only included a few medications such as acetylcho-
linesterase inhibitors (AChEIs) and N-methyl-D-aspartate antagonists (i. 
e., memantine).5-9 For example, a meta-analysis of 17 randomized 
controlled trials (RCTs) showed that AChEIs were superior to placebos in 
improving cognitive function, activities of daily living, and overall 
function in patients with LBD.6 Another meta-analysis of 15 RCTs on 
LBD reported that both AChEIs and memantine improved global 
cognitive function and motor symptoms.7 However these meta-analyses 
provided little information on how and which pharmacotherapy should 
be chosen to treat patients with DLB showing different clusters of core 
features. In addition, findings from studies drawn from a wide spectrum 
of LBD may pose challenges in interpreting responses to DLB alone, as 
neuropathological and genetic differences existed between the two 
groups studied.4 Finally, there are several medications other than 
anti-dementia drugs that were not included in the previous meta--
analyses,6-8 such as antipsychotic,10-16 antidepressant,16 anti--
parkinsonism,17-20 and anticonvulsant medications.21 Therefore, a 
meta-analysis of these drugs is required. 
The majority of pharmacological studies related to the DLB treat-
ment are uncontrolled clinical trials (single treatment arm) and high- 
quality RCTs on DLB are relatively lacking. Thus, there is a lack of 
direct comparisons among RCTs for DLB pharmacotherapies. Network 
meta-analysis (NMA), incorporating direct and indirect evidence 
simultaneously, can generate estimates with precision and accuracy. 
This study aimed to provide credible evidence on the safety and efficacy 
of DLB pharmacotherapies. 
The main objectives of this study were as follows: 1) To compare 
treatment efficacy of RCTs for DLB pharmacotherapies with a NMA 
technique; 2) To obtain optimal efficacy when simultaneously consid-
ering neuropsychiatric, cognitive, and motor symptoms, and the 
acceptability of DLB pharmacotherapies; and 3) To explore the potential 
benefits of DLB pharmacotherapies in RCTs and uncontrolled single-arm 
trials. 
Methods 
Search strategy and selection criteria 
This study was conducted according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) and the PRISMA 
NMA extension statement.22 All clinical trials for DLB 
pharmacotherapies were eligible and included for analyses. All enrolled 
trials were peer-reviewed and published in English. The DLB diagnosis 
was based on consensus guidelines for the clinical and pathological 
diagnosis of DLB.1 This study was registered in PROSPERO 
(CRD42018096996). 
We excluded non-clinical trials (e.g., case reports, case series, and 
observational studies) and studies investigating mixed groups of pa-
tients, such as all-cause dementia or LBD (PDD and DLB), unless the 
articles provided data for the DLB group. 
The following electronic databases were searched from the date of 
their inception to June 5, 2019: PubMed, Medline, Embase, the 
Cochrane Library, and PsycINFO, without any restrictions on age, 
setting, sex, ethnicity, or publication year. The search terms included 
dementia, Lewy bodies, treatment, anti-dementia medication, donepezil, 
rivastigmine, galantamine, memantine, intepirdine, nelotanserin, antide-
pressant, antipsychotic, and pharmacological. Medical subject headings, 
free text terms, and variations were applied, and Boolean operators (OR, 
AND) were used to combine the searches. ClinicalTrials.gov was 
searched to identify unpublished and ongoing studies. Reference lists of 
the included articles and reviews were manually searched to identify 
potentially eligible studies. A search algorithm was developed and 
adapted for each database, without any restrictions on age, setting, sex, 
ethnicity or publication year. Online supplementary data presents the 
full search strategy (supplementary Table S1 and Table S2) and the 
PRISMA checklist (supplementary Table S3). 
Outcomes 
The outcomes were the treatment efficacy and acceptability. Treat-
ment efficacy was defined as mean change scores in neuropsychiatric 
symptoms measured using the Neuropsychiatric Inventory (NPI-10), 
general cognition measured using the Mini-Mental State Examination 
(MMSE), and motor symptoms (extrapyramidal symptoms) measured 
using the Unified Parkinson’s Disease Rating Scale part III (UPDRS-III). 
The obtained scores for measurements other than NPI-10, MMSE, and 
UPDRS-III were converted to the corresponding natural units.23 
Acceptability was defined as all-cause discontinuation, and premature 
discontinuation of treatment for any reason (e.g., lack of efficacy, 
adverse effects, or poor reliability). 
Data extraction and quality assessment 
Review authors worked in pairs to screen and review articles (Chu 
CS, Yang FC, Tsai CK, and Liang CS). When multiple publications from 
the same trial were encountered, studies with the most informative and 
complete datasets were included in the analyses. Risk of bias (ROB) was 
assessed using the Cochrane ROB tool.24 In case of disagreement, 
another two authors (Chen TY and Tseng PT) were consulted to obtain 
consensus. Authors of RCTs and drug manufacturers were contacted 
when clarification was needed regarding raw data, study designs, or 
outcome measurements. Unavailable data were considered missing 
data. 
Statistical analysis 
The primary NMA included nine RCTs under a frequentist frame-
work. A random-effects model with an intention-to-treat analysis was 
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conducted. The effect sizes (ESs) were calculated with 95% confidence 
intervals (CIs), and the efficacy for neuropsychiatric and motor symp-
toms was negative for ESs. Odds ratios were calculated dichotomous 
outcomes. Heterogeneity among the included studies was evaluated 
using the tau value, which is the estimated standard deviation of the 
effect across the included studies. 
Generalized linear mixed models were used for direct and indirect 
comparisons. Indirect comparisons were conducted by transitivity, 
indicating that the differences between treatments A and B could be 
calculated from their comparisons with the treatment C. We calculated 
the relative ranking probabilities for all treatments. The surface under 
the cumulative ranking curve (SUCRA) indicates the percentage of the 
mean rank of each medication relative to an imaginary intervention that 
is the best without uncertainty. When the area under the curve was 
larger, the treatment had a higher rank of benefit for DLB treatment. 
The rankings of all treatment outcomes were illustrated in a rank- 
heat plot, which was used to simultaneously recognize the best and 
worst interventions for the four outcomes (neuropsychiatric, cognitive, 
and motor symptoms and acceptability).25 
We evaluated the potential inconsistency between direct and indirect 
evidence within the network using the node-splitting method. In addi-
tion, we used the design-by-treatment model to evaluate the global 
inconsistency among all NMAs. Publication bias was investigated using 
Egger’s test and visual inspection of comparison-adjusted funnel plots. 
The secondary NMA included both RCTs and uncontrolled single- 
arm trials under a Bayesian framework, and arm-based analysis was 
performed, which allows for the inclusion of single-arm studies and does 
not require a reference treatment for interpretation and contrast effects 
for which a reference group is selected for comparison.26,27 The ESs of 
the secondary NMA were the median values with 95% credible intervals 
(Crls). 
The NMA was performed using R-Project statistical software (version 
3.5.3, R Foundation), and the pcnetmeta and netmeta statistical packages 
were used. The netmeta package calculates the P-score, which is a fre-
quentist analogue to the SUCRA concept in Bayesian NMA methodology. 
Network plots were constructed using the statistical software package 
Stata (version 15, College Station, Texas, USA). The p values for all 
comparisons were two-tailed, and a cutoff point of 0.05 was considered 
statistically significant. 
Results 
The search strategy yielded 5006 records, and 29 studies met our 
inclusion criteria (supplementary Figure S1). Supplementary Table S2 
provides details of the reasons for exclusion. Of the included trials, nine 
were RCTs10,12,16,21,28-32, and 20 were uncontrolled single-arm 
trials.11,13-15,17-20,33-44 
Characteristics of the Included Studies 
Table 1 summarizes the characteristics of the included studies. A 
total of 29 studies were published between 2000 and 2019, of which 13 
investigated pharmacological interventions, including aripiprazole, 
armodafinil, citalopram, donepezil, galantamine, levodopa, memantine, 
olanzapine, quetiapine, risperidone, rivastigmine, yokukansan, and 
zonisamide. 
For the nine RCTs, 467 participants were assigned to the intervention 
group, while 273 were assigned to the placebo group. Pharmacological 
interventions included citalopram, low-dose donepezil (3 or 5 mg), high- 
dose donepezil (10 mg), memantine, low-dose olanzapine (5 mg), high- 
dose olanzapine (10 or 15 mg), quetiapine, risperidone, rivastigmine, 
low-dose zonisamide (25 mg), and high-dose zonisamide (50 mg). We 
did not categorize rivastigmine into high and low doses, as there was 
only a single regimen in this RCT. The mean age was 77.2 years (SD =
5.2) for the treatment group and 75.9 years (SD = 5.4) for the placebo 
group. The mean study duration was 14 weeks (range, 6 - 24 weeks). 
Figure 1 illustrates the network plots of primary and secondary 
outcomes. Each node represents a treatment, and each edge is a treat-
ment comparison. The size of each node was proportional to the number 
of participants subjected to this treatment. The edge width represents 
the number of trials that compared the two treatments. 
NMA of RCTs 
Figure 2 shows the primary results of the NMA, and ESs for each 
treatment were calculated and compared to the placebo. For neuro-
psychiatric symptoms (k = 6, n = 653) (Fig. 2a), none of the treatments 
reached statistical significance because their CIs contained zero. No 
treatment was significantly associated with the exacerbation of neuro-
psychiatric symptoms. 
For general cognition (k = 6, n = 655), Figure 2b shows that low- 
dose and high-dose donepezil were associated with greater improve-
ment than placebo. High-dose donepezil had an increase of 2.00 points 
(95% CIs: 0.69 to 3.31), and low-dose donepezil had an increase of 1.86 
points (95% CIs: 0.58 to 3.15) in the MMSE score, respectively. The 
cognitive effects of rivastigmine did not reach statistical significance 
because of the wide CI. Memantine and quetiapine decreased MMSE 
scores, although the difference was not statistically significant 
For motor symptoms (k = 7, n = 693), Figure 2c demonstrates that 
high-dose zonisamide was associated greater improvement than pla-
cebo, with a decrease of 4.10 points (95% CIs: -7.03 to -1.17) in the 
UPDRS-III score. Other treatments showed favorable effects, without 
statistical significance. For all-cause discontinuation (k = 8, n = 720), no 
difference was observed in all treatments when compared to the pla-
cebo, as shown in Figure 2d. 
Treatment ranking based on RCT evidence 
Figure 3 shows the rank-heat plot based on the SUCRA of the RCT 
evidence. High-dose donepezil showed a statistically significant favor-
able effect in the domain of general cognition and ranked the best 
treatment option among all pharmacotherapies. In the other three do-
mains, high-dose donepezil was superior to placebo with no statistical 
significance. Low-dose donepezil ranked second among all pharmaco-
therapies in the domain of general cognition and the effect was statis-
tically significant. In the domain of neuropsychiatric and motor 
symptoms, low-dose donepezil was superior to placebo, although 
without statistical significance. In the domain of acceptability, low-dose 
donepezil was inferior to placebo with no statistical significance. High- 
dose zonisamide was ranked the best among all pharmacotherapies in 
the domain of motor symptoms, with statistical significance on point 
estimates. In the domain of neuropsychiatric and motor symptoms, high- 
dose zonisamide was superior to placebo with no statistical significance. 
In the domain of acceptability, high-dose zonisamide was inferior to 
placebo, with no statistical significance. 
Inconsistency, publication bias, and ROB in the NMA of RCTs 
The node-splitting and design-by-treatment interaction models of the 
four study outcomes did not show any evidence of inconsistency (sup-
plementary Table S4). The comparison-adjusted funnel plots and Egger’s 
tests did not show any potential publication bias (supplementary 
Figure S2). Supplementary figure S3 shows that none of the included 
studies had high ROB. 
Visual inspection of the potential effect modifiers across treatments and 
studies 
We assessed whether trials of different interventions were similar 
with respect to important clinical characteristics that could potentially 
influence any differences in treatment effects. Supplementary figure S4 
illustrates the distribution across trials of potential effect modifiers. 
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Table 1 
Characteristics of included trials  
Randomized controlled trials (k = 9)            
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Uncontrolled single-arm trials (k = 20)            









Probable DLB MMSE 
NPI 
SAS 
NA 10 wk Aripiprazole 
10.3mg 
11 76 81.8 15 58 9  
Kazui et al., 
(2017) 
Probable DLB 
Outpatients, 60 to 85 
years 












Outpatient 12 wk 20 72.0 20.0 22.0 11.0 NA  
(continued on next page) 
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Table 1 (continued ) 
Randomized controlled trials (k = 9)            





MMSE NPI UPDRS ROB 
Lapid et al., 
(2017) 
Probable DLB 
Outpatients, 50 to 90 
years 
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Probable DLB MMSE Outpatient 4 wk Donepezil 
10mg 
24 80.5 62.5 18.0 NA NA  
Onofrj et al., 
(2013) 
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NPI-10 
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Lucetti et al., 
(2010) 
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50 76.5 42.0 20.8 27.0 18.8  
Molloy et al., 
(2006) 
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MMSE NA 20 wk Donepezil 
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NA NA  
Iwakasi et al., 
(2005) 
Probable DLB MMSE 
NPI-10 
NA 4 wk Yokukansan 
with unknown 
mg 





































NA 8 wk Quetiapine 
44mg 








11 77.0 NA NA NA 40.0  











Walker et al., 
(1999) 
Probable DLB MMSE NA 12 wk Olanzapine 
4.5mg 
8 81.4 37.5 15.7 NA NA  
Abbreviation: ADCS-ADL23 = Alzheimer’s Disease Cooperative Study Activities of Daily Living, 23 Items; BEHAVE-AD = Behavioral Symptoms in Alzheimer’s Disease; 
BIS = Behavioral Impairment Scale; BPRS = Brief Psychiatric Rating Scale; DLB = Dementia of Lewy bodies; MMSE = Mini-Mental State Examination; NPI =
Neuropsychiatric Inventory; NPI-NH = Neuropsychiatric Inventory- Nursing Home version; NPI-10 = 10-Item Neuropsychiatric Inventory Sub-score; UPDRS-III =
Unified Parkinson’s Disease Rating Scale Part 3, ROB = risk of bias; SAS = Simpson-Angus Scale. 
* McKeith et al., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international 
workshop. Neurology 1996, 47:1113–1124. 
a Scores are from Simpson-Angus scale. 
b Scores are from Behavioral Impairment Scale. 
c Scores are from Behavioral Symptoms in Alzheimer’s Disease. 
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Notably, the study by Cummings et al.12 was the only study that used 
olanzapine to manage patients with DLB. However, this study recruited 
patients with DLB with severely impaired cognition; these patients were 
older and there was a higher proportion of female patients in the study. 
Another RCT by Culo et al.16 investigated the efficacy of risperidone vs. 
citalopram and had distinct study characteristics; however, this study 
did not contribute to study outcomes because it did not have a common 
comparator placebo. As only nine RCTs were recruited, we did not 
conduct meta-regression analysis to examine the influence of potential 
effect modifiers, as this generally requires large study numbers for 
reliable estimation. 
NMA of RCTs and uncontrolled single-arm trials 
The results of the secondary NMA with RCTs and uncontrolled single- 
arm trials are shown in Figure 4 and were used to reveal the potential 
benefits of each treatment. For neuropsychiatric symptoms (k = 27, n =
1073) (Fig. 4a), aripiprazole, low-dose olanzapine, yokukansan, and 
high-dose donepezil were significantly associated with improvement in 
NPI-10 scores compared with the placebo. 
For general cognitive function (k = 30, n = 1117) (Fig. 4b), the re-
sults were similar to those of the primary NMA in that high-dose and 
low-dose donepezil were positively associated with the MMSE score 
compared to the placebo. Notably, levodopa was associated with 
cognitive impairment, with a decrease of 3.4 points (95% Crls: -5.1 to 
-1.4) in the MMSE score. For motor symptoms (k = 20, n = 960) 
(Fig. 4c), low-dose and high-dose zonisamide were significantly associ-
ated with decreases in the UPDRS-III score compared to the placebo. 
Other treatments showed favorable effects, but the differences were not 
statistically significant. For all-cause discontinuation (k = 35, n = 1231) 
(Fig. 4d), citalopram and risperidone were significantly associated with 
increased odds when compared to the placebo. 
Figure 1. Network meta-analysis of eligible comparisons for the neuropsychiatric symptoms. 
HD = high-dose; LD = low-dose. 
Figure 2. The forest plots of network meta-analysis of RCTs for (a) neuropsychiatric symptoms, (b) general cognition, (c) motor symptoms, and (d) all-cause 
discontinuation. The estimated effects were compared with placebo. 
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Discussion 
Our NMA presents the most comprehensive overview of the available 
data on the safety and efficacy of DLB pharmacotherapies. Based on RCT 
data, the primary NMA provided credible evidence for DLB manage-
ment, with precision and accuracy. Secondary NMA with RCTs and 
uncontrolled single-arm trials explored potential options for DLB treat-
ments that require further investigation with large-scale RCTs. 
Our study revealed that high-dose and low-dose donepezil were 
associated with cognitive improvement when compared with the pla-
cebo. For motor symptoms, only high-dose zonisamide significantly 
improved motor symptoms. For all-cause discontinuation, none of the 
included interventions showed higher odds of all-cause discontinuation 
than the placebo. 
Previous studies reported inconsistent findings on the efficacy of 
memantine in neuropsychiatric symptoms of LBD.9,45 Pairwise 
meta-analytic studies also showed no difference with memantine 
treatment for alleviating neuropsychiatric symptoms in both DLB and 
PDD.7,8 A recent meta-analytic study found that memantine improved 
neuropsychiatric symptoms in DLB but not PDD in a sub-group analysis.9 
Another RCT also reported that the improvement in neuropsychiatric 
symptoms with memantine was only observed in DLB but not PDD.28 In 
the present study, memantine showed favorable effects on neuropsy-
chiatric symptoms, with no statistical significance. However, since only 
one RCT28 and one uncontrolled clinical trial44 were included for ana-
lyses, more well-conducted RCTs are required to confirm the robustness 
and accuracy of these results. 
The International DLB Consortium has endorsed the use of AChEIs 
(donepezil and rivastigmine) in treating neuropsychiatric symptoms in 
patients with DLB.1 The Delphi consensus group also supports the 
beneficial effects of donepezil and rivastigmine on neuropsychiatric 
symptoms in patients with LBD.45 However, previous meta-analytic 
studies reported a distinct effect of AChEIs between DLB and PDD, 
showing that donepezil and rivastigmine improved neuropsychiatric 
Figure 3. The rank-heat plot based on SURCA.  
Figure 4. The forest plots of network meta-analysis of RCTs plus uncontrolled single-arm trials for (a) neuropsychiatric symptoms, (b) general cognition, (c) motor 
symptoms, and (d) all-cause discontinuation. 
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symptoms in PDD but not in DLB. 8,9 The primary NMA in the present 
study showed that both donepezil and rivastigmine were not associated 
with greater improvement in neuropsychiatric symptoms than placebo, 
while high-dose donepezil showed favorable effect on neuropsychiatric 
symptoms, observed in the secondary NMA. 
The Delphi consensus group45 and the British Association for Psy-
chopharmacology46 have recommended the use of rivastigmine and 
donepezil in both PDD and DLB for the improvement of cognitive 
function. Furthermore, the DLB Consortium supports the use of AChEIs 
in DLB.1 However, our primary NMA revealed that high-dose and 
low-dose donepezil were significantly associated with cognitive 
improvement, but not rivastigmine, which is supported by a recent 
meta-analytic study showing greater improvement of cognitive function 
found with donepezil in DLB, and with rivastigmine in PDD.9 Donepezil 
is a reversible inhibitor, whereas rivastigmine is an irreversible inhibi-
tor, which can explain why duration of action for donepezil is short 
lasting in comparison with that for rivastigmine.47 Thus, DLB and PDD 
may respond to individual AChEI treatment differently, and hence, 
AChEIs treatment regimens should be carefully considered with the 
precise differentiation of LBD diagnoses. 
In general, patients with PDD are subjected to long-term and high- 
dose antiparkinsonian medications, while patients with DLB may be 
naïve to antiparkinsonian medication. Therefore, the management of 
motor symptoms in patients with DLB and PDD may be markedly 
different. In our NMA, we found that only high-dose zonisamide was 
associated with a greater improvement in motor symptoms. Both high- 
dose and low-dose zonisamide showed improvements in motor symp-
toms in secondary NMA. Importantly, levodopa was not significantly 
associated with motor symptom improvement, while it may impair 
general cognition, showing a decrease of 3.4 points (-5.1 to -1.4) in the 
MMSE score. A previous study reported that one-third of patients with 
DLB receiving levodopa showed motor benefits, while worsened psy-
chosis was observed in one-third of patients.19 To date, and the risk of 
worsened cognitive function of levodopa has not been specifically 
addressed in DLB management. The trade-off between cognitive func-
tion, psychotic symptoms, and parkinsonism should be considered when 
prescribing levodopa to patients with DLB. 
In the secondary group, yokukansan associated with a greater 
improvement in neuropsychiatric symptoms. Moreover, it did not 
worsen cognitive function and was well tolerated. Yokukansan, a Jap-
anese formula, consists of seven herbs and is derived from Yi-Gan San of 
traditional Chinese medicine.48 Another noteworthy finding is that ari-
piprazole provided the best effectiveness in improving neuropsychiatric 
symptoms, and it did not exert negative effects on cognitive function and 
motor symptoms in patients with DLB; however, the evidence was 
derived from one small uncontrolled single-arm trial.15 Further RCTs are 
needed to validate the overall efficacy of yokukansan and aripiprazole in 
DLB. 
Limitations 
There were some limitations to this study. First, only nine RCTs were 
recruited; therefore, the current NMA may be underpowered. Although 
the point estimates appear beneficial, several treatments did not reach 
statistical significance. Moreover, the inconsistency test may also be 
subject to low statistical power. Second, the study by Cummings et al.12 
had distinct study characteristics. Therefore, the estimated treatment 
effect of olanzapine may be influenced by these potential effect modi-
fiers. Third, the evidence of zonisamide was solely derived from one 
RCT21 where zonisamide was used as an adjunct to levodopa. Therefore, 
the effect of zonisamide on motor symptoms needs to be interpreted 
with caution. Third, most of the comparisons of our NMA came from 
indirect evidence, and the network structure was not extensively con-
nected. Therefore, the generalizability of our findings may be limited. 
Fourth, because most of the DLB studies were uncontrolled single-arm 
trials, we used a contrast-based approach for the NMA of RCTs and an 
arm-based approach for the NMA of RCTs plus uncontrolled single-arm 
trials. The aim of the arm-based NMA was to explore the potential 
benefits of the treatments. Therefore, the findings of our arm-based 
NMA should be viewed as provisional and hypothesis-generating. 
Given that the findings of the present study were based on a primary 
NMA with only nine RCTs and a secondary NMA with most uncontrolled 
single-arm trials, the findings should be interpreted cautiously. 
In conclusion, the management of DLB remains challenging. Treat-
ment of a single symptom may have a trade-off with others. The NMA 
included evidence from available RCTs and provided the most 
comprehensive evidence for the selection of pharmacotherapy for 
treating different clusters of DLB-related symptoms. The rank-heat plot 
may assist clinicians in quickly recognizing the most effective treatment 
in each domain for overall consideration when making decisions for 
treatment. More well-conducted RCTs for DLB pharmacotherapies are 
needed to warrant treatment recommendations with precision and ac-
curacy with NMA findings, including donepezil, zonisamide, aripipra-
zole, and yokukansan. 
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